HIV exposed seronegative individuals show antibodies specifically recognizing native HIV envelope glycoprotein

AIDS

Volumn 27, Issue 9, 2013, Pages 1375-1385

  Carrillo, Jorge ^a   Restrepo, Clara ^b   Rallón, Norma I ^b   Massanella, Marta ^a   Del Romero, Jorge ^c   Rodríguez, Carmen ^c   Soriano, Vincent ^b   Clotet, Bonaventura ^a,d   Benito, Jose M ^b   Blanco, Julià ^a  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^c HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^d FUNDACIÓ INSTITUT D INVESTIGACIÓ EN CIÈNCIES DE LA SALUT GERMANS TRIAS I PUJOL   (Spain)

Author keywords

Conformational epitopes; Natural antibodies; Protection; Soluble CD4 induced epitopes transmission

Indexed keywords

GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 140; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; VIRUS ENVELOPE PROTEIN;

ADULT; ARTICLE; BLOOD ANALYSIS; CELL SURFACE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNE RESPONSE; INFECTION RESISTANCE; INFECTION RISK; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; SERODIAGNOSIS;

ADULT; AGED; ANTIGENS, CD4; CASE-CONTROL STUDIES; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES; FEMALE; HIV ANTIBODIES; HIV SERONEGATIVITY; HIV-1; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; SEXUAL PARTNERS;

EID: 84879121537     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32835fac08     Document Type: Article

References (46)

1. Quinn TC. Global burden of the HIV pandemic. Lancet 1996; 348:99-106.
2. Royce RA, Seña A, Cates W, Cohen MS. Sexual transmission of HIV. N Engl J Med 1997; 336:1072-1078.
3. Balzarini J, Van Damme L. Microbicide drug candidates to prevent HIV infection. Lancet 2007; 369:787-797.
4. Simon V, Ho DD, Abdool Karim Q. HIV/AIDS epidemiology, pathogenesis, prevention, and treatment. Lancet 2006; 368: 489-504.
5. Haase AT. Early events in sexual transmission of HIV and SIV and opportunities for interventions. Annu Rev Med 2011; 62:127-139.
6. Gray RH, Wawer MJ, Brookmeyer R, Sewankambo NK, Serwadda D, Wabwire-Mangen F, et al. Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. Lancet 2001; 357:1149-1153.
7. Restrepo C, Rallón NI, Carrillo J, Soriano V, Blanco J, Benito JM. Host factors involved in low susceptibility to HIV infection. AIDS Rev 2011; 13:30-40.
8. Miyazawa M, Lopalco L, Mazzotta F, Lo Caputo S, Veas F, Clerici M, et al. The 'immunologic advantage' of HIV-exposed seronegative individuals. AIDS 2009; 23:161-175.
9. Young JM, Turpin JA, Musib R, Sharma OK. Outcomes of a National Institute of Allergy and Infectious Diseases Workshop on understanding HIV-exposed but seronegative individuals. AIDS Res Hum Retroviruses 2011; 27:737-743.
10. Erickson AL, Willberg CB, McMahan V, Liu A, Buchbinder SP, Grohskopf LA, et al. Potentially exposed but uninfected individuals produce cytotoxic and polyfunctional human immunodeficiency virus type 1-specific CD8(R) T-cell responses which can be defined to the epitope level. Clin Vaccine Immunol 2008; 15:1745-1748.
11. Fowke KR, Kaul R, Rosenthal KL, Oyugi J, Kimani J, Rutherford WJ, et al. HIV-1-specific cellular immune responses among HIV-1-resistant sex workers. Immunol Cell Biol 2000; 78:586-595.
12. Kaul R, Dong T, Plummer FA, Kimani J, Rostron T, Kiama P, et al. CD8(R) lymphocytes respond to different HIV epitopes in seronegative and infected subjects. J Clin Invest 2001; 107:1303-1310.
13. Kaul R, Rowland-Jones SL, Kimani J, Fowke K, Dong T, Kiama P, et al. New insights into HIV-1 specific cytotoxic T-lymphocyte responses in exposed, persistently seronegative Kenyan sex workers. Immunol Lett 2001; 79:3-13.
14. Pallikkuth S, Wanchu A, Bhatnagar A, Sachdeva RK, Sharma M. Human immunodeficiency virus (HIV) gag antigen-specific T-helper and granule-dependent CD8 T-cell activities in exposed but uninfected heterosexual partners of HIV type 1-infected individuals in North India. Clin Vaccine Immunol 2007; 14:1196-1202.
15. Restrepo C, Rallón NI, del Romero J, Rodríguez C, Hernando V, López M, et al. Low-level exposure to HIV induces virus-specific T cell responses and immune activation in exposed HIV-seronegative individuals. J Immunol 2010; 185:982-989.
16. Lizeng Q, Nilsson C, Sourial S, Andersson S, Larsen O, Aaby P, et al. Potent neutralizing serum immunoglobulin A (IgA) in human immunodeficiency virus type 2-exposed IgG-seronegative individuals. J Virol 2004; 78:7016-7022.
17. Nguyen M, Pean P, Lopalco L, Nouhin J, Phoung V, Ly N, et al. HIV-specific antibodies but not t-cell responses are associated with protection in seronegative partners of HIV-1-infected individuals in Cambodia. J Acquir Immune Defic Syndr 2006; 42:412-419.
18. Burastero SE, Gaffi D, Lopalco L, Tambussi G, Borgonovo B, De Santis C, et al. Autoantibodies to CD4 in HIV type 1-exposed seronegative individuals. AIDS Res Hum Retroviruses 1996; 12:273-280.
19. Lo Caputo S, Trabattoni D, Vichi F, Piconi S, Lopalco L, Villa ML, et al. Mucosal and systemic HIV-1-specific immunity in HIV-1-exposed but uninfected heterosexual men. AIDS 2003; 17:531-539.
20. Lopalco L, Pastori C, Cosma A, Burastero SE, Capiluppi B, Boeri E, et al. Anticell antibodies in exposed seronegative individuals with HIV type 1-neutralizing activity. AIDS Res Hum Retroviruses 2000; 16:109-115.
21. Hasselrot K, Bratt G, Hirbod T, Säberg P, Ehnlund M, Lopalco L, et al. Orally exposed uninfected individuals have systemic anti-HIV responses associating with partners' viral load. AIDS 2010; 24:35-43.
22. Lopalco L, Barassi C, Pastori C, Longhi R, Burastero SE, Tambussi G, et al. CCR5-reactive antibodies in seronegative partners of HIV-seropositive individuals down-modulate surface CCR5 in vivo and neutralize the infectivity of R5 strains of HIV-1 In vitro. J Immunol 2000; 164:3426-3433.
23. Bomsel M, Tudor D, Drillet AS, Alfsen A, Ganor Y, Roger MG, et al. Immunization with HIV-1 gp41 subunit virosomes induces mucosal antibodies protecting nonhuman primates against vaginal SHIV challenges. Immunity 2011; 34:269-280.
24. Letvin NL, Rao SS, Dang V, Buzby AP, Korioth-Schmitz B, Dombagoda D, et al. No evidence for consistent virus-specific immunity in simian immunodeficiency virus-exposed, uninfected rhesus monkeys. J Virol 2007; 81:12368-12374.
25. Kaul R, Rowland-Jones SL, Kimani J, Dong T, Yang HB, Kiama P, et al. Late seroconversion in HIV-resistant Nairobi prostitutes despite preexisting HIV-specific CD8R responses. J Clin Invest 2001; 107:341-349.
26. Barretina J, Blanco J, Bonjoch A, Llano A, Clotet B, Esté JA. Immunological and virological study of enfuvirtide-treated HIV-positive patients. AIDS 2004; 18:1673-1682.
27. Blanco J, Barretina J, Clotet B, Esté JA. R5 HIV gp120-mediated cellular contacts induce the death of single CCR5-expressing CD4 T cells by a gp41-dependent mechanism. J Leukoc Biol 2004; 76:804-811.
28. Sánchez-Palomino S, Massanella M, Carrillo J, García A, García F, González N, et al. A cell-to-cell HIV transfer assay identifies humoral responses with broad neutralization activity. Vaccine 2011; 29:5250-5259.
29. Blanco J, Barretina J, Ferri KF, Jacotot E, Gutiérrez A, Armand-Ugón M, et al. Cell-surface-expressed HIV-1 envelope induces the death of CD4 T cells during GP41-mediated hemifusion-like events. Virology 2003; 305:318-329.
30. Lopalco L. Humoral immunity in HIV-1 exposure: cause or effect of HIV resistance? Curr HIV Res 2004; 2:127-139.
31. Mazzoli S, Lopalco L, Salvi A, Trabattoni D, Lo Caputo S, Semplici F, et al. Human immunodeficiency virus (HIV)-specific IgA and HIV neutralizing activity in the serum of exposed seronegative partners of HIV-seropositive persons. J Infect Dis 1999; 180:871-875.
32. Tudor D, Derrien M, Diomede L, Drillet AS, Houimel M, Moog C, et al. HIV-1 gp41-specific monoclonal mucosal IgAs derived from highly exposed but IgG-seronegative individuals block HIV-1 epithelial transcytosis and neutralize CD4(R) cell infection: an IgA gene and functional analysis. Mucosal Immunol 2009; 2:412-426.
33. Lopalco L, Barassi C, Paolucci C, Breda D, Brunelli D, Nguyen M, et al. Predictive value of anticell and antihuman immunodeficiency virus (HIV) humoral responses in HIV-1-exposed seronegative cohorts of European and Asian origin. J Gen Virol 2005; 86:339-348.
34. Li M, Gao F, Mascola JR, Stamatatos L, Polonis VR, Koutsoukos M, et al. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol 2005; 79:10108-10125.
35. Koshiba T, Chan DC. The prefusogenic intermediate of HIV-1 gp41 contains exposed C-peptide regions. J Biol Chem 2003; 278:7573-7579.
36. Sullivan N, Sun Y, Sattentau Q, Thali M, Wu D, Denisova G, et al. CD4-Induced conformational changes in the human immunodeficiency virus type 1 gp120 glycoprotein: consequences for virus entry and neutralization. J Virol 1998; 72:4694-4703.
37. Alter G, Moody MA. The humoral response to HIV-1: new insights, renewed focus. J Infect Dis 2010; 202 (Suppl 2):S315-S322.
38. Casali P, Schettino EW. Structure and function of natural antibodies. Curr Top Microbiol Immunol 1996; 210:167-179.
39. Zhou Z-H, Zhang Y, Hu Y-F, Wahl LM, Cisar JO, Notkins AL. The broad antibacterial activity of the natural antibody repertoire is due to polyreactive antibodies. Cell Host Microbe 2007; 1:51-61.
40. Centers for Disease Control and Prevention (CDC). False-positive serologic tests for human T-cell lymphotropic virus type I among blood donors following influenza vaccination, 1992. MMWR Morb Mortal Wkly Rep 1993; 42:173-175.
41. Bogers WMJM, Davis D, Baak I, Kan E, Hofman S, Sun Y, et al. Systemic neutralizing antibodies induced by long interval mucosally primed systemically boosted immunization correlate with protection from mucosal SHIV challenge. Virology 2008; 382:217-225.
42. Suy A, Castro P, Nomdedeu M, García F, López A, Fumero E, et al. Immunological profile of heterosexual highly HIVexposed uninfected individuals: predominant role of CD4 and CD8 T-cell activation. J Infect Dis 2007; 196:1191-1201.
43. Holl V, Peressin M, Moog C. Antibody-mediated Fc(receptor-based mechanisms of HIV inhibition: recent findings and new vaccination strategies. Viruses 2009; 1:1265-1294.
44. Moody MA, Liao H-X, Alam SM, Scearce RM, Plonk MK, Kozink DM, et al. Antiphospholipid human monoclonal antibodies inhibit CCR5-tropic HIV-1 and induce beta-chemokines. J Exp Med 2010; 207:763-776.
45. Tomescu C, Abdulhaqq S, Montaner LJ. Evidence for the innate immune response as a correlate of protection in human immunodeficiency virus (HIV)-1 highly exposed seronegative subjects (HESN). Clin Exp Immunol 2011; 164:158-169.
46. Liao H-X, Chen X, Munshaw S, Zhang R, Marshall DJ, Vandergrift N, et al. Initial antibodies binding to HIV-1 gp41 in acutely infected subjects are polyreactive and highly mutated. J Exp Med 2011; 208:2237-2249. Investigación en SIDA SIDA